Skip to main content
. 2021 Jul 14;11:720125. doi: 10.3389/fonc.2021.720125

Figure 6.

Figure 6

Validation of the expression and overall survival of CTLA4/HAVCR2 in KIRC. (A, B) The expression of CTLA4/HAVCR2 in KIRC and normal renal tissues. (C, D) The overall survival curve of CTLA4/HAVCR2 in KIRC patients in high and low expression cohort. ***p < 0.001.